SC 13G: Sunshine Biopharma, Inc
Ticker: SBFMW · Form: SC 13G · Filed: Feb 23, 2024 · CIK: 1402328
| Field | Detail |
|---|---|
| Company | Sunshine Biopharma, Inc (SBFMW) |
| Form Type | SC 13G |
| Filed Date | Feb 23, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Sunshine Biopharma, Inc.
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Sunshine Biopharma, Inc (ticker: SBFMW) to the SEC on Feb 23, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
What are the key financial figures in this filing?
Key dollar amounts include: $0.001 (Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti).
How long is this filing?
Sunshine Biopharma, Inc's SC 13G filing is 3 pages with approximately 911 words. Estimated reading time is 4 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 911 words · 4 min read · ~3 pages · Grade level 9.7 · Accepted 2024-02-23 16:03:01
Key Financial Figures
- $0.001 — Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securiti
Filing Documents
- l1cap_13g.htm (SC 13G) — 31KB
- 0001079973-24-000295.txt ( ) — 32KB
Ownership
Item 4. Ownership. (a)–(c) The information required by Items 4(a)-(c) is set forth in Rows (5)-(9) and Row (11) of the cover page and is incorporated herein by reference. The percentage set forth on Row (11) of the cover page for the reporting person is based on 99,452,861 Common Stock outstanding based on the Issuer’s filings with the Securities and Exchange Commission and related information. David Feldman and Joel Arber are the Directors of L1 Capital Global Opportunities Master Fund, Ltd. As such, L1 Capital Global Opportunities Master Fund, Ltd., Mr. Feldman, and Mr. Arber may be deemed to beneficially own (as that term is defined in Rule 13d-3 under the Securities Exchange Act of 1934) the issuer’s securities described herein. To the extent Mr. Feldman and Mr. Arber are deemed to beneficially own such securities, Mr. Feldman and Mr. Arber disclaim beneficial ownership of these securities for all other purposes. Item 5. If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following Item 6. Not applicable. Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person. Not applicable. Item 8. Identification and Classification of Members of the Group. Not applicable. Item 9. Notice of Dissolution of Group. Not applicable. Item 10. Certifications. By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participa
SIGNATURES
SIGNATURES After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete, and correct. By: L1 Capital Global Opportunities Master Fund, Ltd. February 23, 2024 By: /s/ David Feldman David Feldman, Director